PCF 2019 VL

The Transformative Development and Progress of The Prostate Cancer Clinical Trials Consortium - Howard Scher, Michael Morris, and Jake Vinson

Details
Charles Ryan is joined by the leadership of the Prostate Cancer Clinical Trials Consortium, a group that has developed innumerable trials and therapies for advanced prostate cancer. The Prostate Cancer Clinical Trials Consortium (PCCTC) was initiated in 2005 by the Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP) in response to criti...

The Intersection of Cardiovascular Disease and Genitourinary Cancer Treatments - Javid Moslehi

Details
Javid Moslehi joins Alicia Morgans in a conversation on the cardiovascular health of cancer patients. Javid Moslehi's laboratory focuses on mechanistic understanding of cardiovascular toxicities that result from novel “targeted” cancer therapies. In this conversation, they discuss the cardiovascular toxicities associated with androgen deprivation therapy (ADT) and the physiologic mechanisms and ma...

Testosterone Replacement in the Treatment of Advanced Prostate Cancer - Sam Denmeade and Michael Schweizer

Details
Sam Denmeade and Michael Schweizer join Charles Ryan at the 2019 Prostate Cancer Foundation Retreat (PCF 2019) to discuss testosterone replacement in advanced prostate cancer. The three discuss the impact of testosterone on prostate cancer cells, recent clinical trials involving testosterone replacement and the risks and benefits of adding this therapy to one’s treatment plan for prostate cancer p...

RET Signaling in Neuroendocrine Prostate Cancer - Justin Drake

Details
Justin Drake, University of Minnesota, discusses the latest and ongoing research associated with the correlation between RET gene expression and neuroendocrine prostate cancer. The recent data shows enhanced RET gene expression in patients that have this AR negative neuroendocrine positive phenotype. Drake also highlighted his work in the development of noninvasive ways of detecting RET signaling...

Women Pursuing a Career in Medicine: Highlights on the Prostate Cancer Foundation Scientific Retreat - Alicia Morgans

Details
Kamari Collins, Laila Williams, and Valerie Martinez from San Diego High School join Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to share their visions for their own futures based upon their experiences as a part of the science, Technology, Engineering, and Math (STEM) program at MedTech Academy in San Diego, California. These three dedicated young wo...

Systemic Therapies in High Volume & Low Volume Disease in the Treatment of Metastatic Hormone Sensitive Prostate Cancer from the STAMPEDE Trial- Nick James

Details
Nick James, a Professor of Clinical Oncology at the Institute of Cancer Research joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses the developments around the high-volume/low-volume disease in metastatic hormone-sensitive disease from the STAMPEDE trial. They also discuss relapsed disease versus de novo metastatic disease. Biographies: P...

Monoallelic vs Biallelic BRCA2 Alterations, PARP Inhibitors in Prostate Cancer - Colin Pritchard

Details
Colin Pritchard joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) where they discuss PARP inhibitor data that came out of the 2019 ESMO meeting including the PROfound study data, rucaparib in TRITON2, and niraparib in the GALAHAD study and focusing on monoallelic versus biallelic BRCA2 alterations. Biographies: Colin C Pritchard, M.D., Ph.D. is the Dire...

Aggressive Variant Prostate Cancer: Identifying Patients with Specific Molecular Signature - Ana Aparicio

Details
Ana Aparicio discusses her work with aggressive variant prostate cancer and her group’s research using immunohistochemistry results and genomic analysis to identify patients with a specific molecular signature. The research concludes that this molecular signature appears to identify the people that benefit from the addition of carboplatin to cabazitaxel chemotherapy. People that have the signature...

Precision Oncology Program for Cancer of the Prostate (POPCaP) - Matthew Rettig

Details
Matt Rettig discusses POPCaP and his work involving the health of veterans with prostate cancer and ongoing clinical trials going on exclusively within the Veterans Health Administration (VA) system. The Precision Oncology Program for Cancer of the Prostate (POPCaP), a partnership between the VA and the Prostate Cancer Foundation (PCF) to create a system of excellence for prostate cancer in VA is...

The Impact of Vitamin D and Statins on Prostate Cancer Outcomes - Lorelei Mucci and Elizabeth Platz

Details
Lorelei Mucci and Elizabeth Platz join Charles Ryan in a discussion on the impact of vitamin D and statins on prostate cancer outcomes. There is no direct evidence linking vitamin D and the risk of prostate cancer, however, vitamin D is believed to be important for overall good health. There is an inverse relationship between cholesterol and risk for the development of prostate cancer and statin u...